Condition: Cardiotoxicity · HER2-positive Breast Cancer · Sponsor: Odense University Hospital
Due to a risk of heart failure during HER2 directed therapy in breast cancer, treatment is monitored with imaging of myocardial function, which is resource demanding for both patients and the health care system. The purpose of this study is to evaluate, if biomarkers can replace imaging based examinations of myocardial function during HER2 directed therapy.
This description comes directly from the study's public registry record.
Ann Banke, MD, PHD · +4526278303 · Ann.Banke@rsyd.dk
Always discuss trial participation with your own doctor first.
| Aalborg University Hospital | Aalborg, Denmark | Recruiting |
| Rigshospitalet | Copenhagen, Denmark | Recruiting |
| Herlev University Hospital | Herlev, Denmark | Not Yet Recruiting |
| Odense University Hospital | Odense, Denmark | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05406635